BMS’s Reblozyl (luspatercept) Receives Health Canada Approval for Beta Thalassemia

 BMS’s Reblozyl (luspatercept) Receives Health Canada Approval for Beta Thalassemia

BMS’s Reblozyl (luspatercept) Receives Health Canada Approval for Beta Thalassemia

Shots:  

  • The approval is based on the P-lll BELIEVE study assessing Reblozyl (luspatercept) + BSC vs PBO + BSC in adult patients with anemia associated with beta-thalassemia requiring regular RBC transfusions
  • Result: ≥33% reduction in RBC transfusion with a reduction of ≥2units from 13-24wks. (21.4% vs. 4.5%), results were published in NEJM
  • Reblozyl regulate late-stage RBC maturation to potentially reduce the number of regular RBC transfusions and is the first and only erythroid maturation agent approved in Canada

Click here ­to­ read full press release/ article | Ref: BMS | Image: MPR

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post